Clinical Edge Journal Scan

Higher total vitamin D intake tied to reduced risk for early-onset CRC


 

Key clinical point: Higher vitamin D intake was associated with a lower risk for early-onset colorectal cancer (CRC) in younger women. The risk reduction was mainly driven by dietary vitamin D.

Major finding: The risk for CRC was significantly lower in women younger than 50 years of age with 450 or higher IU/day (hazard ratio [HR], 0.49) or 300 to less than 450 IU/day (HR, 0.51) vsvs less than 300 IU/day ( P for trend = .01) of total vitamin D intake. The risk reduction was significant and stronger for dietary vsvs supplemental vitamin D (HR per 400 IU/day increase, 0.34; 95% confidence interval, 0.15-0.79).

Study details: Findings are from a prospective cohort study of 94,205 female nurses aged 25-42 years from the Nurses’ Health Study II.

Disclosures: The study was supported by grants from the National Institutes of Health, Department of Defense, American Cancer Society Mentored Research Scholar, and Project P Fund. AT Chan, C Fuchs, and K Ng reported receiving consulting fees, research funding, and/or serving as a consultant and/or a scientific advisor for various sources.

Source: Kim H et al. Gastroenterology. 2021 Jul 6. doi: 10.1053/j.gastro.2021.07.002 .

Recommended Reading

Performance matters in adenoma detection
MDedge Hematology and Oncology
Early-onset CRC associated with longer survival
MDedge Hematology and Oncology
Antibiotic linked to rise in early onset colon cancer?
MDedge Hematology and Oncology
Mutational signature may reveal underlying link between red meat and CRC
MDedge Hematology and Oncology
Good survival, outcomes with TARE for HCC in practice
MDedge Hematology and Oncology
Higher preoperative dietary fiber intake may reduce complications after CRC surgery
MDedge Hematology and Oncology
No benefit of adding pembrolizumab to neoadjuvant chemoradiotherapy in LARC
MDedge Hematology and Oncology
Survival correlates with response to preoperative chemotherapy in CRPM patients undergoing CRS/HIPEC
MDedge Hematology and Oncology
Efficacy of EGFR treatment for metastatic CRC differs with primary tumor location
MDedge Hematology and Oncology
Adherence to CRC screening programs essential even in asymptomatic average-risk individuals
MDedge Hematology and Oncology